Receive The Newest Study Notifications

The expansion to 20 clinical trial sites in Canada and the US will accelerate the SERENITY© study  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced it is ready to resume its Phase 3 clinical program in advanced cancer pain...

In the last few years the number of clinical trials looking for new treatments for Leukemia (AML) has continued to grow. In 2017, a report from ManagedCare said that: "… There are over 400 phase 2 or phase 3 trials currently recruiting or underway for the treatment of...

Pivotal Study to Evaluate Potential of Anti-CD3 Monoclonal Antibody to Intercept Type 1 Diabetes Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it...

NanOlogy may offer an alternative treatment option for patients with bladder cancer Investigational drug, NanoDoce, is injected locally into tumor resection bed via cystoscope guidance followed by intravesical instillation NanOlogy, a clinical-stage oncology company,...

Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B and age-related diseases, today announced that it has entered into a strategic collaboration with Shanghai Junshi Biosciences Co.,...

MERLIN is one of four separate clinical trials studying ORBCEL stromal cell immunotherapies designed to treat some of the most challenging diseases Orbsen Therapeutics, a biotechnology company focused on the development and commercialization of first-in-class stromal...

The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.) (TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, announced today that SB623, a regenerative cell therapy that the Group is developing globally for the treatment of chronic motor...

Asepticys LLC, a leading innovator and developer of anti-infective pharmaceutical and consumer healthcare products, today announced the successful completion of multi-site human clinical trials for Asepticys' novel contact lens care solution containing TriFlect™...

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology,...

The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of National Taiwan University VolitionRx Limited has announced that it has added to its extensive clinical trial program with the execution of a non-binding...

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has achieved enrollment milestones in two...

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary NK-engager (TriKE) platform and Multi-Target Bispecific Drug Conjugate (MTBDC) platform, announced today it has...

Company Will Host Conference Call at 5:00 p.m. (ET) on Monday, April 8, 2019 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today...

First Clinical Trial to Evaluate the Potential of the Personal Neoantigen Vaccine NEO-PV-01 in Combination with Standard of Care in First-Line Metastatic NSCLC Treatment Setting Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company...

All Primary Efficacy and Safety Endpoints, and Key Secondary Endpoints Achieved Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance...

The National Cancer Institute's (NCI) National Clinical Trials Network (NCTN) recently designated the MCW Cancer Center as a Lead Academic Participating Site (LAPS) for the strength and innovation of its ongoing research and science and robust participation in its...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or HER2...

Company Announced IND Clearance Today for Phase 1/2 Clinical Trial Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today preclinical data demonstrating that HMI-102, its gene therapy candidate for the treatment of phenylketonuria (PKU),...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP). RRP is an HPV-associated...

SCYNEXIS, Inc.. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced data demonstrating the potential use of ibrexafungerp as an agent to address multiple serious fungal...